Novigenix
17.1.2024 08:02:15 CET | ACCESS Newswire | Press release
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
7 Days Left: LiberNovo Maxis, Big & Tall's Ultimate Seat9.6.2026 11:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / June 9, 2026 / Built from the ground up for larger frames, the Maxis series launches June 16 starting at €829, with super early bird savings up to 48% off MSRP. For Big & Tall buyers, the ergonomic chair search usually starts with the spec sheet. Most chairs in this segment are built on the standard ergonomic envelope and scaled up, not designed for a larger body in the first place. LiberNovo's Maxis series, launching June 16, is the brand's first line engineered from the start for that body. It ships in three configurations alongside two new additions to the LiberNovo Omni family. A larger geometry, by design Standard ergonomic chairs are sized for a body that runs around 5'9" and 170 pounds. Maxis is sized for the bodies that don't fit those numbers. Its 52 cm seat extends fully under the thigh, so the front edge won't cut off circulation by mid-afternoon. The frame is BIFMA-certified to 181 kg (399 lb), supported by a die-cast aluminum alloy base th
Family Online Safety Institute Hosts 2026 European Forum in Brussels, Convening Global Leaders to Find Common Ground on Online Safety9.6.2026 07:30:00 CEST | Press release
New Research on Australia's Social Media Ban Released Alongside Day of Sessions with OECD, Ofcom, and Global Industry Leaders BRUSSELS, BE / ACCESS Newswire / June 9, 2026 / The Family Online Safety Institute (FOSI) is pleased to host its 2026 European Forum, "Finding Common Ground," taking place today at Google's offices in Brussels, Belgium. This Forum brings together policymakers, regulators, researchers, industry leaders, and civil society organizations from across Europe and beyond to explore one central question: how can we find common ground on online safety? Throughout the day, attendees will explore developments in online safety regulation, emerging research on children's digital wellbeing, the growing role of AI in the lives of families, and realistic approaches to creating safer digital experiences for young people and families. Featured sessions include a discussion with representatives from the OECD, Ofcom, and Arcom, ATKM, and Belgium's Institute for Postal Services and T
Three Polaris Projects in Mexico Selected Under the Mixed Development Program9.6.2026 01:40:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 8, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") announced that Mexico's Secretary of Energy (Secretaría de Energía, "SENER"), and the Federal Electricity Commission (Comisión Federal de Electricidad, "CFE") have completed the first national competitive selection process under the CFE Mixed Development Program. The process was launched through a Request for Proposals ("RfP") issued in February 2026, with submitted projects evaluated in accordance with the Guidelines for Mixed Development Programs published by SENER in January 2026. On June 5, 2026, CFE and SENER announced that the final award volume exceeded the original target, with approximately 8,000 MW of projects selected for advancement under the program. As part of this award process, Polaris is pleased to announce that all three Polaris-owned projects submitted under the Mixed Development Program have been selected to advance to the final contract negotiation st
GA-ASI Announces Investments in Six Dutch Companies8.6.2026 18:00:00 CEST | Press release
New Slate of Business Partnerships Established Following the Last Blue Magic Netherlands Event SAN DIEGO, CA / ACCESS Newswire / June 8, 2026 / General Atomics Aeronautical Systems, Inc. (GA‑ASI) is deepening its footprint in the Dutch innovation ecosystem, with new investments in six Netherlands-based technology companies through its Blue Magic Netherlands (BMN) venturing initiative. These new partnerships follow the latest BMN event in Eindhoven, a fast-paced, "shark tank"-style forum in which Dutch startups and scaleups pitched breakthrough technologies directly to GA‑ASI decision makers. The most recent edition drew more than 350 attendees from across the country's aerospace, defense, and high-tech communities. Building on the success of prior events, GA‑ASI has selected six Dutch companies for new investment and collaboration. GA-ASI also is increasing its investment in Emergent Swarm, first discovered at BMN 2024. Emergent Swarm is partnering with GA‑ASI to further mature its swa
SK Tes Ireland Achieves ISO Certification Milestone and Recognized in National Digital Infrastructure Report4.6.2026 15:00:00 CEST | Press release
DUBLIN, IE / ACCESS Newswire / June 4, 2026 / SK tes, a global leader in sustainable technology lifecycle services, today announced that its Ireland facility has successfully passed audits for ISO 9001 (Quality Management), ISO 14001 (Environmental Management), ISO 45001 (Occupational Health & Safety), and ISO 27001 (Information Security Management), reinforcing its commitment to delivering consistent, high-quality, safe and sustainable services worldwide. These certifications are standard across SK tes' global network of facilities and form a core part of the company's operating model. As the newest site within this network, Ireland's certification reflects the structured commissioning process that ensures every SK tes location meets the same rigorous international standards - enabling clients to receive a consistent, secure, and compliant service experience, regardless of geography. In parallel, the Irish business has been recognized in the DII Economic Report 2026, published by Digi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom